Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Achim Heinecke

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2006
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemiaThomas Büchner, Wolfgang E Berdel, Claudia Schoch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative GroupThomas Büchner, Wolfgang Hiddemann, Wolfgang E Berdel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2005
Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96)Peter Koch, Andreas Probst, Wolfgang E Berdel, et al.
Blood|March 13, 2009
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)Friederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Blood|August 22, 2008
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Manuela Hummel, Clara D Bloomfield, et al.
Blood|March 1, 2012
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotypeFriederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Critical Reviews in Oncology/Hematology|October 26, 2005
Treatment of older patients with AMLThomas Büchner, Wolfgang E Berdel, Bernhard Wörmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 25, 2013
Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysisMatthias Stelljes, Utz Krug, Dietrich W Beelen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studiesTorsten Haferlach, Claudia Schoch, Helmut Löffler, et al.
Blood|January 10, 2009
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCGJan Braess, Karsten Spiekermann, Peter Staib, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2006
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemiaThomas Büchner, Wolfgang E Berdel, Claudia Schoch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative GroupThomas Büchner, Wolfgang Hiddemann, Wolfgang E Berdel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2005
Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96)Peter Koch, Andreas Probst, Wolfgang E Berdel, et al.
Blood|March 13, 2009
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)Friederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Blood|August 22, 2008
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Manuela Hummel, Clara D Bloomfield, et al.
Blood|March 1, 2012
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotypeFriederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Critical Reviews in Oncology/Hematology|October 26, 2005
Treatment of older patients with AMLThomas Büchner, Wolfgang E Berdel, Bernhard Wörmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 25, 2013
Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysisMatthias Stelljes, Utz Krug, Dietrich W Beelen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studiesTorsten Haferlach, Claudia Schoch, Helmut Löffler, et al.
Blood|January 10, 2009
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCGJan Braess, Karsten Spiekermann, Peter Staib, et al.
Pageof 8